MASLD & MASH Global Consensus Recommendations Paper
Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are linked to significant health risks, reduced quality of life, and a considerable economic burden. Although numerous national and international guidelines exist, inconsistencies among them have led to confusion and suboptimal patient care. To address this, the Global NASH/MASH Council (GNC) conducted a comprehensive review of MASLD and MASH guidelines published between 2018 and 2025. Using a structured Delphi consensus development process, the GNC harmonized these diverse recommendations. Following the analysis of 61 documents and completion of four Delphi rounds, a unified set of global consensus recommendations was established. These recommendations are presented in a clear, evidence-based framework that includes summary tables and clinical algorithms. The guidance is intended to support healthcare professionals in the effective management of MASLD and MASH—particularly in the context of existing and emerging therapies.
Read the full article here: https://www.gastrojournal.org/
Focused Recommendations for the Management of MASH by Advanced Practice Providers (APPs) in the United States
In the United States, patient care and clinical decision making is often performed independently by APPs, namely nurse practitioners (NPs) and physician assistants (PAs). In this paper, expert APP members of the GNC’s APP committee outline strategies for MASH management by APPs. The recommendations emphasize the use of noninvasive tests (NITs) to identify patients at risk of liver-related outcomes, particularly those with stages 2-3 fibrosis. The FDA approval of resmetirom for noncirrhotic MASH and emerging therapies offer new treatment options beyond lifestyle changes, equipping APPs to navigate the evolving MASH treatment landscape effectively.
Read the full article here: https://journals.lww.com/jcge/fulltext/2025/04000/focused_recommendations_for_the_management_of.3.aspx